信立泰 (002294)

Shenzhen Salubris Pharmaceuticals Co., Ltd.

ASZ

Tags

MSCI Mid Cap IndexGeneric DrugsWeight Loss DrugsInnovation 100 IndexInnovative DrugsPharmaceutical ManufacturingFund Heavy PositionsCCTV 50 IndexPlanned Reduction of HoldingsConsumption 100 IndexPearl River DeltaSocial Security Fund Heavy PositionsHigh-Performing StocksMargin Trading and Securities LendingChina Securities Finance and Central Huijin HoldingsNon-Cyclical StocksHigh-Dividend StocksSME & ChiNext 100 IndexSME 100 IndexSME 300 IndexSZSE 300 IndexSZSE Innovation Index

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 111481.65
  • Circulating A-Shares(W): 111456.57
  • Earnings Per Share(RMB): 0.5200
  • Net Assets Per Share(RMB): 7.8690
  • Operating Revenue(W RMB): 324129.68
  • Total Profit(W RMB): 65069.88
  • Net Profit Attributable to Parent(W RMB): 58070.66
  • Net Profit Growth Rate(%): 13.93
  • Weighted Return on Equity(%): 6.6700
  • Operating Cash Flow Per Share(RMB): 0.6970
  • Undistributed Profit Per Share(RMB): 4.5921
  • Capital Reserve Per Share(RMB): 1.7692

2. Main Business

The main business covers:

  • Research, production, and sales of pharmaceuticals and medical devices.
  • Patent licensing.

3. Company Basic Information

  • Company Name: Shenzhen Salubris Pharmaceuticals Co., Ltd.
  • Listing Date: 2009-09-10
  • Industry: Pharmaceutical Manufacturing
  • Address: 37th Floor, Greenview Plaza, 6009 Shennan Avenue, Futian District, Shenzhen, Guangdong Province
  • Website: www.salubris.com
  • Company Profile: Shenzhen Salubris Pharmaceuticals Co., Ltd. is a foreign-invested joint-stock company established on June 29, 2007, through the overall transformation of Shenzhen Salubris Pharmaceutical Co., Ltd., approved by the Ministry of Commerce.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Salubris Pharmaceutical Co., Ltd. General Legal Person 63527.94 57.00
2 China Europe Healthcare Hybrid Securities Investment Fund A Class Fund 2717.92 2.44
3 Hong Kong Securities Clearing Company Ltd. Northbound Capital 1892.12 1.70
4 Shenzhen Runfu Investment Development Co., Ltd. General Legal Person 1546.60 1.39
5 Central Huijin Asset Management Co., Ltd. Special Legal Person 1406.67 1.26
6 Shenzhen Salubris Pharmaceuticals Co., Ltd. - Phase III Employee Stock Ownership Plan Asset Management Plan 1340.89 1.20
7 ICBC Credit Suisse Frontier Healthcare Equity Securities Investment Fund A Class Fund 1280.00 1.15
8 National Social Security Fund 114 Portfolio Social Security Fund 992.75 0.89
9 ChinaAMC Innovation Medicine Theme Hybrid Securities Investment Fund A Class Fund 860.19 0.77
10 Yinhua CSI Innovation Pharmaceutical Industry ETF Fund 541.12 0.49

5. Concept Sectors

  • Generic Drugs
  • Innovative Drugs
  • Weight Loss Drugs
  • Margin Trading & Securities Lending
  • High-Performance Stocks
  • Social Security Fund Heavy Holdings
  • Fund Heavy Holdings
  • National Team (CICC & Huijin) Holdings
  • Planned Reduction
  • MSCI Mid Cap
  • Non-Cyclical Stocks
  • High Dividend Stocks
  • Zhongchuang 100
  • SME 100
  • SZSE 300
  • Consumption 100
  • CCTV 50
  • SME 300
  • SZSE Innovation Index
  • Innovation 100
  • Pearl River Delta

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information